

MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia

Milan (Italy), February 27th, 2017 – MolMed S.p.A. (“MolMed”) and Rocket Pharmaceuticals Ltd. (“Rocket Pharma”) signed a development and manufacturing service agreement on a gene therapy product for the treatment of Fanconi Anemia.

Rocket Pharma is a leading US gene therapy company based in New York, NY, with both an advancing clinical program and several preclinical programs. All programs are focused on developing curative treatments for rare genetic conditions with high unmet need.

Pursuant to this agreement, MolMed will develop and manufacture the lentiviral vectors to be used for the *ex-vivo* transduction of hematopoietic stem cells, as part of the manufacturing process of Rocket’s cellular therapy products intended for clinical trials and in related research and development activities.

Riccardo Palmisano, MolMed’s CEO commented: *“We are pleased to announce this new collaboration agreement signed with a company as well-positioned in cell and gene therapy field as Rocket Pharma: it once again confirms MolMed’s well recognised excellence in development and manufacturing of cell and gene therapy products, reinforcing one of the two pillars on which our Company plans to build its future growth, and represents a possible first step towards a broader strategic collaboration with this really promising company”.*

This press release is written in compliance with public disclosure obligations established by Consob’s (Italian securities & exchange commission) Issuers Regulation.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

About Rocket Pharma

For more information about Rocket Pharmaceuticals Ltd, please visit www.rocketpharma.com.

For further information:

MolMed S.p.A.:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

telefono: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@segrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..